Welcome to our dedicated page for Lifecore Biomedical SEC filings (Ticker: LFCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SEC filings for a sterile injectable CDMO like Lifecore Biomedical (LFCR) can feel like navigating a lab notebook鈥攄ense with GMP jargon, hyaluronic acid production stats and quality-system validations. If you've ever searched for 鈥�Lifecore Biomedical SEC filings explained simply,鈥� you know the challenge of extracting CDMO revenue trends or spotting fermentation capacity disclosures buried deep in a 300-page report.
Stock Titan solves that problem. Our AI identifies what matters in every document, from the Lifecore Biomedical annual report 10-K simplified to each Lifecore Biomedical quarterly earnings report 10-Q filing. Instantly surface segment margins, backlog changes and risk-factor shifts. Need real-time alerts? We stream Lifecore Biomedical Form 4 insider transactions real-time, flagging executive stock sales the moment they hit EDGAR. For sudden contract wins or FDA updates, the platform breaks down Lifecore Biomedical 8-K material events explained so you grasp the impact without parsing legalese.
- Track Lifecore Biomedical insider trading Form 4 transactions alongside price charts.
- Compare fermentation vs. fill-finish performance with our Lifecore Biomedical earnings report filing analysis.
- Review board pay in the latest Lifecore Biomedical proxy statement executive compensation.
- Save hours by understanding Lifecore Biomedical SEC documents with AI summaries.
- Monitor Lifecore Biomedical executive stock transactions Form 4 before key announcements.
Every filing type鈥�10-K, 10-Q, 8-K, Form 4鈥攍ands here seconds after EDGAR posts, complete with plain-English context and expert commentary. Whether you鈥檙e modeling capacity expansion or checking compliance milestones, our AI-powered analysis turns Lifecore鈥檚 complex disclosures into actionable insight.
Lifecore Biomedical reported material weaknesses in its internal control over financial reporting, identifying deficiencies in Information and Communication, Control Activities and Monitoring. The company said the weaknesses relate to accounting and classification of non-standard transactions, inventory valuation, capitalization of interest on assets under construction, recognition of development revenue and related cost of sales, presentation of operating costs for continuing and discontinued operations, and write-offs of receivables from its former Curation Foods businesses. Management concluded that, as of May 25, 2025, these deficiencies remained aggregated as material weaknesses. The Audit Committee discussed the issues with BDO, authorized BDO to respond to KPMG inquiries, and filed BDO's letter as Exhibit 16 to the Form 8-K.
Lifecore Biomedical intends to use a presentation in discussions with investors, analysts and others and has furnished that presentation as Exhibit 99.1 to this Current Report. The company says the Presentation will be posted on its investor relations website and that the material furnished in this Item (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Exchange Act nor incorporated by reference into future Securities Act filings unless expressly stated.
This disclosure is a Regulation FD furnishing of investor materials and confirms where the Presentation will be available; the report is signed by the company's Chief Financial Officer.
FAQ
What is the current stock price of Lifecore Biomedical (LFCR)?
What is the market cap of Lifecore Biomedical (LFCR)?
